Insight

Chinmay Jani Highlights Need for Comprehensive Genomic Testing in HER2-Positive Tumors

Chinmay Jani/LinkedIn

Aug 22, 2025, 09:10

Chinmay Jani Highlights Need for Comprehensive Genomic Testing in HER2-Positive Tumors

Chinmay Jani, Chief Fellow at Sylvester Comprehensive Cancer Center, shared on X:

“Check out our recent analysis The Oncologist under mentorship of Aakash Desai of 653 solid tumors evaluating HER2 by IHC, CNV and mutational profiling.

Results:

IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg
CN amplification: 3.1% (75% IHC3+)
Pathogenic ERBB2 mutations: 3.1% (only 5% IHC3+)

ERBB2-mut tumors rarely show IHC3+/CN amp → highlights need for comprehensive genomic testing.

In the era of pan-tumor T-DXd approval, integrating genomic + phenotypic data can refine patient selection and advance precision oncology.”

Title: HER2 Alterations across Solid Tumors: Implications for Comprehensive Testing

Authors: Ahmed Ismail , Chimay Jani , Nusrat Jahan , Malla Midhun , Arnab Basu , Garima Gupta , Bassel El-Rayes , Sejong Bae , Tyler Mattox , Cyntanna Hawkins , Rebecca C Arend , Mehmet Akce , Yanis Boumber , Aakash Desai

Read the full article.

Chinmay Jani

More posts featuring Chinmay Jani.

Aakash Desai Ahmed Ismail Arnab Basu Bassel El Rayes cancer Chinmay Jani Cyntanna Hawkins Garima Gupta Malla Midhun Mehmet Akce Nusrat Jahan OncoDaily Oncology Rebecca C Arend Sejong Bae Tyler Mattox Yanis Boumber

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer